drugset / Trial / NCT06932315

A Study to Evaluate the Safety, Tolerability and Dose-Response Relationship of HRS-9190 in Healthy Subjects

NCT06932315

Phase 1 Completed 53 enrolled Jiangsu HengRui Medicine Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a single-center, open-label and dose-escalation study to evaluate the safety, tolerability and dose-response relationship of HRS-9190 in healthy adults.

Timeline

Start
2025-04-23
Primary completion
2025-08-13
Completion
2025-08-13

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-9190 Unknown

Indications

No indication recorded.